139481-72-4

Basic information

• Product Name: Trityl candesartan
• Synonyms: Candesartan N1-Trityl IMpurity;2-Ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-c;(Trityl candesartan)2-Ethoxy-1-[[2-(2-Triphenyl Methyl)-2H-Tetrazole-5-YL](1,1-Biphenyl)-4-YL]Methyl]Benzimidazole-2-Carboxylic Acid;1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-;2-Ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-;2-ethoxy-1-[[(2'-(1-triphenylmethyl-1h-tetrazol-5-yl)biphenyl-4-yl)methyl]benzimidazole-7-carboxylic acid;TRITYL CANDESARTAN;Triphenyl Candesartan
• CAS NO: 139481-72-4
• Molecular Formula: C₄₃H₃₄N₆O₃
• Molecular Weight: 682.77
• EINECS: 1806241-263-5
• Product Categories: INTERMEDIATESOF;Candesartan Cilexetil;API intermediates;Intermediates of Candesartan;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 139481-72-4.mol
• Article Data: 15

Chemical Properties

• Melting Point: 163-165°C
• Boiling Point: 908.6 °C at 760 mmHg
• Flash Point: 503.3 °C
• Appearance: white powder
• Density: 1.26 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.677
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly, Heated)
• PKA: 2.06±0.10(Predicted)
• CAS DataBase Reference: Trityl candesartan(CAS DataBase Reference)
• NIST Chemistry Reference: Trityl candesartan(139481-72-4)
• EPA Substance Registry System: Trityl candesartan(139481-72-4)

Safety Data

• Hazardous Substances Data: 139481-72-4(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 139481-72-4 differently. You can refer to the following data:
1. 2-Ethoxy-1-((2''-(1-trityl-1H-tetrazol-5-yl)-[1,1''-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylic Acid can be used as reagent/reactant in preparation of the anti-hypertensive drug candesartan cilexetil.
2. Candesartan analog as angiotensin II antagonist.

InChI:InChI=1/C43H34N6O3/c1-2-52-42-44-38-24-14-23-37(41(50)51)39(38)48(42)29-30-25-27-31(28-26-30)35-21-12-13-22-36(35)40-45-46-47-49(40)43(32-15-6-3-7-16-32,33-17-8-4-9-18-33)34-19-10-5-11-20-34/h3-28H,2,29H2,1H3,(H,50,51)

Upstream product

• 596-43-0 bromo-triphenyl-methane 
• 139481-59-7 candesartan 
• 139481-44-0 methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-benzimidazole-7-carboxylate 
• 139481-58-6 ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]benzimidazole-7-carboxylate 
• 139481-41-7 ethyl 1-[(2'-cyano-[1,1']-biphenyl-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate 
• 73833-13-3 acid chloride of 1-methylhydrogen-3-nitrophthalate 
• 139481-28-0 methyl 2-<<2'-cyanobiphenyl-4-yl)methyl>amino>-3-nitrobenzoate 
• 603-11-2 3-nitrophthalic acid 
• 136304-78-4 methyl 3-amino-2-[[(2'-cyanobiphenyl-4-yl)methyl]amino]benzoate 
• 139481-69-9 methyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate 
• 57113-90-3 methyl 2-(N-tert-butoxycarbonylamino)-3-nitrobenzoate 
• 21606-04-2 methyl 2-carboxy-3-nitrobenzoate 
• 821-25-0 1,1-dichloroheptane 
• 76-83-5 trityl chloride 

Relevant articles and documents

Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth in vitro and in vivo

Ubiquitin-like protein neddylation is overactivated in various human cancers and correlates with disease progression, and targeting this pathway represents a valuable therapeutic strategy. Our previous work disclosed an antihypertensive agent, candesartan cilexetic (CDC), serves as a novel neddylation inhibitor for suppressing tumor growth by targeting Nedd8-activating enzyme (NAE). In this study, 42 benzimidazole derivatives were designed and synthesized based on lead compound CDC to improve the neddylation inhibition and anticancer efficacy. Optimal benzimidazole-derived 35 displayed superior neddylation inhibition in enzyme assay compared to CDC (IC50 = 5.51 μM vs 16.43 μM), along with promising target inhibitory activity and killing selectivity in cancer cell. The results of cellular mechanism research combined with tumor growth suppression in human lung cancer cell A549 in vivo, accompanied with docking model, revealed that 35 has the potential to be developed as a promising neddylation inhibitor for anticancer therapy.

METHOD FOR PREPARING TRITYL CANDESARTAN

The present invention uses a candesartan cyclic compound as a starting material and performs thereon a three-step reaction of forming tetrazole, hydrolysis and adding a protecting group to directly obtain trityl candesartan without separating an intermediate product via crystallization. The operating process is simple and thus is more applicable to industrial production.

PROCESS FOR PREPARATION OF CANDESART AN CILEXETIL SUBSTANTIALLY FREE OF DES-CANDESARTAN CILEXETIL IMPURITY

The present invention provides a process for preparation of candeartan cilexetil substantially free of 2,3-dihydro-2-oxo-3-[[2'-(2H-tetrazol-5-yl)[l,l-biphenyl]-4- yl]methyl]-l-[[(cyclohexyloxy)carbonyl]oxy]ethylester-lH-benzimidazole-7- carboxylate (des-candesartan cilexetil) impurity.